Viridian Therapeutics to begin Phase III trials of thyroid eye disease treatment [Yahoo! Finance]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
Named REVEAL-1 and REVEAL-2, the trials aim to assess the efficacy and safety of the subcutaneous doses of VRDN-003 in people with both active and chronic TED, respectively. The two double-masked, randomised, placebo-controlled trials are due to begin in August this year. REVEAL-1 will involve nearly 84 subjects, who will be randomised in a 1:1:1 ratio to receive either VRDN-003 or a placebo every four or eight weeks. The dosing will begin with a 600mg loading dose, administered as two 300mg injections, followed by 300mg injections at subsequent intervals. The REVEAL-2 trial will include around 126 patients undergoing the same randomisation and dosing regimens. Proptosis responder rate, as assessed by a minimum of 2mm improvement in proptosis at week 24 compared to baseline, will be the primary endpoint for both trials. Viridian expects to release top-line data from these trials in the first half of 2026 and aims to submit a biologics license application (BLA) by the end
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now? [Yahoo! Finance]Yahoo! Finance
- Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year [Seeking Alpha]Seeking Alpha
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.MarketBeat
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $29.00 price target on the stock.MarketBeat
VRDN
Earnings
- 5/8/24 - Beat
VRDN
Sec Filings
- 6/28/24 - Form 4
- 6/28/24 - Form 4
- 6/28/24 - Form 4
- VRDN's page on the SEC website